Literature DB >> 2617176

Epidemiology of oesophageal reflux disease.

R C Heading1.   

Abstract

Because of inconsistency in terminology and history of diagnosis of gastro-oesophageal reflux disease, accurate epidemiologic information is difficult to compile. Historically, heartburn has been recognised as the classic symptom of gastro-oesophageal reflux disease. Five per cent of the Western adult population experiences heartburn with some frequency. Heartburn may be the sole basis for diagnosis, but many patients have less specific symptoms that do not allow a reliable diagnosis solely from clinical features. No more than two-thirds of patients with gastro-oesophageal reflux disease have oesophagitis on endoscopy. The peak age distribution for patients with gastro-oesophageal reflux disease ranges between 60 and 70 years. Clinical reports concerning long-term natural history and management are scarce. In some patients there is spontaneous improvement without drug therapy. Five to 10% of patients referred to the hospital with gastro-oesophageal reflux disease require antireflux surgery, but most patients are treated by primary-care physicians.

Entities:  

Mesh:

Year:  1989        PMID: 2617176

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  23 in total

1.  What is heartburn worth? A cost-utility analysis of management strategies.

Authors:  G R Heudebert; R M Centor; J C Klapow; R Marks; L Johnson; C M Wilcox
Journal:  J Gen Intern Med       Date:  2000-03       Impact factor: 5.128

2.  Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials.

Authors:  M Rothman; C Farup; W Stewart; L Helbers; J Zeldis
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

3.  Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease.

Authors:  C M Bate; P D Richardson
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 4.  Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact.

Authors:  Richard N Fedorak; Sander Veldhuyzen van Zanten; Ron Bridges
Journal:  Can J Gastroenterol       Date:  2010-07       Impact factor: 3.522

Review 5.  Treatment of gastroesophageal reflux disease.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

6.  Gastroesophageal reflux disease: clinical features.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

7.  Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain.

Authors:  Jürgen E Andrich; Michael Wobben; Peter Klotz; Oliver Goetze; Carsten Saft
Journal:  J Neural Transm (Vienna)       Date:  2009-09-22       Impact factor: 3.575

8.  Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients.

Authors:  E Kuster; E Ros; V Toledo-Pimentel; A Pujol; J M Bordas; L Grande; C Pera
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

9.  Cholecystectomy and oesophageal pathology: is there a link?

Authors:  S Jazrawi; T N Walsh; P J Byrne; T P Hennessy
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

10.  Three year follow up of patients with gastrooesophageal reflux disease.

Authors:  N E Schindlbeck; A G Klauser; G Berghammer; W Londong; S A Müller-Lissner
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.